These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20579699)

  • 41. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
    Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
    Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H
    Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
    Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
    Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [pT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence].
    Barry Delongchamps N; Peyromaure M; Kpatcha F; Beuvon F; Legrand G; Zerbib M
    Prog Urol; 2012 Feb; 22(2):100-5. PubMed ID: 22284594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is there a prostate-specific antigen upper limit for radical prostatectomy?
    Gontero P; Spahn M; Tombal B; Bader P; Hsu CY; Marchioro G; Frea B; Van Der Eeckt K; Kneitz B; Frohneberg D; Tizzani A; Van Poppel H; Joniau S
    BJU Int; 2011 Oct; 108(7):1093-100. PubMed ID: 21392220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
    Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
    Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The association between pre-operative PSA and prostate cancer-specific mortality in patients with long-term follow-up after radical prostatectomy.
    Lewinshtein D; Teng B; Valencia A; Gibbons R; Porter CR
    Prostate; 2012 Jan; 72(1):24-9. PubMed ID: 21520159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Preoperative predictive model for biochemical recurrence in patients with localized prostate cancer treated with radical prostatectomy].
    Molina Escudero R; Herranz Amo F; Paez Borda A; Hernández Fernández C
    Arch Esp Urol; 2013; 66(6):567-75. PubMed ID: 23985457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.
    Ganzer R; Robertson CN; Ward JF; Brown SC; Conti GN; Murat FJ; Pasticier G; Rebillard X; Thuroff S; Wieland WF; Blana A
    BJU Int; 2011 Oct; 108(8 Pt 2):E196-201. PubMed ID: 21332907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
    Sasaki T; Onishi T; Hoshina A
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
    Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
    Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
    Yoshida T; Matsuzaki K; Kobayashi Y; Takeda K; Nakayama M; Arai Y; Kakimoto K; Nishimura K
    Int Urol Nephrol; 2012 Apr; 44(2):479-85. PubMed ID: 21822599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.